1) Strategy & Leadership - Alexandria Real Estate Equities (ARE) is focused on enabling the life science industry to develop life-saving therapies, emphasizing the importance of strong translational research and innovation. - The company aims to maintain a strong balance sheet while reducing capital expenditure and funding needs. - Leadership challenges persist at NIH and FDA, impacting the regulatory environment and funding dynamics. - The company is committed to its path forward, which includes improving occupancy and net operating income (NOI) while managing general and administrative expenses.

2) Financial & Segment Results - FFO per share diluted as adjusted for Q1 2026 was $1.73, with a reaffirmed guidance midpoint for 2026 at $6.40. - Leasing volume for the quarter was 647,000 square feet, impacted by lower renewals and no public biotech leases, which account for 24% of annual rental revenue. - Occupancy decreased to 87.7%, down 320 basis points from the previous quarter, primarily due to key lease expirations. - Same-property NOI declined 11.9%, driven by reduced occupancy, with an updated guidance range for 2026 indicating a decline of 9.5%.

3) Problems / Headwinds - The operating environment remains challenging, with no public biotech leases signed in Q1 2026, a first for the company. - The company faces pressures from leadership changes at regulatory bodies and ongoing scrutiny of drug pricing. - The anticipated occupancy and NOI performance has been downgraded due to a shift in asset disposition strategies, with more assets held than previously planned.

4) Operational or Product Plans - ARE is focused on leasing vacant space, with 1.1 million square feet expected to deliver in September 2026. - The company has signed letters of intent for 394,000 square feet in development and redevelopment projects. - There is a strategic pivot towards advanced technology tenants, with ongoing evaluations of several projects for potential changes in use. - The company plans to recycle capital through dispositions and joint ventures, targeting $2.9 billion in sales for 2026.

5) Guidance & Outlook / Investor Angle - Guidance for occupancy has been revised down to 87% for year-end 2026, reflecting a more conservative outlook on asset sales and leasing activity. - The company remains optimistic about capturing leasing demand in its largest markets, outperforming its market share significantly. - The anticipated impact of AI on real estate needs remains neutral, with no significant changes in tenant demand observed yet. - The company is prioritizing its fundraising efforts to support capital needs before considering stock repurchases.

Bottom line: Alexandria Real Estate Equities is navigating a challenging environment with strategic adjustments to its leasing and capital plans. While facing headwinds from regulatory uncertainties and market dynamics, the company remains committed to its long-term vision and is positioned to capitalize on its strong tenant base and asset quality. Shareholders should monitor the execution of its path forward and the potential for improved occupancy and NOI in the second half of 2026.